A new approach to discovering targets for Alzheimer’s and other neurodegenerative diseases has been presented by Insilico Medicine with the University of Cambridge, UK.
Mission Bio has launched a tool it claims will help save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six months faster.
Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
Celgene, Triphase Accelerator, and Facit entered a collaboration for a first-in-class preclinical therapeutic, targeting the WDR5 protein for the treatment of leukemia and other blood cancers.
Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.
Absorption Systems has announced a technology licensing agreement with Pfizer Inc., in which the pharma company will use the preclinical CRO’s cell lines to test potential drug candidates.
AstraZeneca has partnered with Bicycle Therapeutics in a potential $1bn deal to develop a new class of small molecules which have antibody-like properties.
The US FDA has cleared Adaptimmune to start a trial of its fat cancer cell therapy, lifting the clinical hold imposed in August when the agency asked for more manufacturing data.
AMRI and the University at Albany’s RNA Institute are partnering to speed the development of new RNA-based therapeutics in an “ideal and first of its kind” collaboration.
The US FDA has ordered Adaptimmune to halt a trial of its candidate liposarcoma therapy and asked for more information about how the treatment is made.
Triazamacrocyclic lipid complexes increase the efficiency of antibody-drug conjugates (ADCs) by delivering the payload right into the heart of a cancer cell, says BioCellChallenge.
Microbial expression systems are cheaper and more efficient than mammalian cell cultures says BioSilta which has acquired the rights to an E. coli based platform.
Protea Biosciences has teamed up with Agilent Technologies to offer drugmakers mass spectrometry alternatives to UV detection in QA/QC of recombinant proteins.
A team of researchers has modified a lectin protein found in bananas to diminish its inflammatory properties, potentially setting it on the path to use as an antiviral.
Irish scientists have completed the most comprehensive structural study yet of a PEGylated protein, giving greater insight into how such molecules improve injectable therapies.
Hamburg, Germany-based Evotec and Sanofi are launching a strategic collaboration in diabetes drug development that could be worth as much as $330m (€303m) for the German company, including €3m upfront.
Merck Millipore has entered an agreement whereby it will control and manage the Singulex Life Science Research business, which offers a technology that can provide ultra-sensitive protein detection.
A drug candidate which prevents the export of viral RNA in infected cells could lead the way in developing a functional cure for HIV, according to Abivax.
Contract research organization (CRO) Horizon has been selected as a “core facility” for supplying biopharma research tools to academic group the Tri-Institutional Therapeutics Discovery Institute.
Analytical and bioanalytical service provider SGS has made significant changes to its global network over the past few months to stay ahead of the competition curve.
A group of researchers at Harvard Medical School has developed a strongly cationic nanoparticle that physically absorbs proteins to form a new type of drug-carrier complex in aqueous solution.
Malvern Instruments will buy GE Healthcare’s MicroCal business in a deal that adds protein analysis and formulation development tech to its expanding drug industry offering.
US scientists have tinkered with a virus so that it opens its cargo doors only in the presence of certain enzymes that could be used to drop therapeutics precisely onto a target.
CMO Cytovance Biologics has entered into a manufacturing agreement with Pamlico Biopharma to develop a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.
Cobra says it will no longer need to rely on third-parties for its biologics quality control tests after receiving an extension to its GMP certification at a Swedish facility.
Cambridge Isotope Laboratories (CIL) is working with Nexomics Biosciences to provide isotope-labeled proteins to nearly all of the world’s largest pharmaceutical companies.
Linking peptide and small molecule drugs to albumin will improve pharmacokinetics, says Almac as it partners its manufacturing capabilities with Novozymes’ half-life extension platform.
Agilent Technologies and SomaLogic will partner to expand the dissemination of Soma’s proteomic assay to at least five academic and contract research centers by the end of the year as demand for the tool has skyrocketed among biopharma companies.
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
Cobra Biologics is confident it can win the commercial contract for Vaccibody AS’ candidate DNA vaccine, citing its production platform and recent capacity expansion as key.
